President Trump’s Executive Order Clears A Path For Fort Hood Soldiers To Benefit From Texas Ibogaine Research

Texas is moving forward with research on a psychedelic drug after President Trump removed barriers to research. This development is great news for Fort Hood soldiers suffering from PTSD and other central Texans fighting opioid addictions.

Texas Pioneers State-Led Psychedelic Research After Corporate Partners Pass

Texas officials announced that the state will launch its own independent research program into Ibogaine. This decision comes after the state failed to find a private drug company capable of meeting the stringent requirements for a joint venture to develop the psychedelic into an FDA-approved medication.

President Trump Clears the Way

The program received significant support on April 18, when President Trump signed an executive order to facilitate national research into psychedelics like Ibogaine for treating mental health conditions.The executive order directs the Food and Drug Administration to issue new guidance on the use of psychedelic drugs intended for clinical trials for U.S. veterans suffering from Post Traumatic Stress Disorder The order includes an additional $50 million federal investment to support state-led programs like the one in Texas.

A $50 Million Commitment Meets a Federal Boost

The initiative, spearheaded by Lt. Gov. Dan Patrick and House Speaker Dustin Burrows, utilizes $50 million in taxpayer funds allocated by the Legislature last year under Senate Bill 2308. While several drug companies submitted proposals, lawmakers said that none met the state's high standards, which included a corporate presence in Texas and a commitment to match the $50 million investment.

What is Ibogaine?

Ibogaine is made from an ancient African shrub and is known for its potential to treat PTSD, traumatic brain injury (TBI), and severe addiction. While it remains an illegal substance federally, it has gained bipartisan support in Texas due to its reported success in treating military veterans.

Navigating the "Risk" of Research

According to the Texas Tribune, Katharine Neill Harris, a drug policy fellow at Rice University’s Baker Institute, suggested that the state’s requirements, which included a 20% revenue share for Texas, may have been too demanding for private companies in such a high-risk field.Currently, UTHealth Houston, in collaboration with UTMB Galveston, is set to lead a two-year clinical trial.

Leading a Multi-State Coalition

Despite the lack of a private developer, advocates like Bryan Hubbard of Americans for Ibogaine believe Texas is creating a blueprint for other states. Legislatures in Mississippi, Oklahoma, and Tennessee are watching closely, potentially joining a multi-state research effort that Hubbard says is "far more significant than one private developer."